DevsHealth provides an AI‑driven drug discovery platform, DevsHealth OS, that combines advanced data analytics, high‑precision molecular modeling, and continuous learning to accelerate the design of antiviral and antimicrobial candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Developing new drugs for infectious diseases is traditionally slow, costly, and fraught with high failure risk, limiting the ability to respond quickly to emerging pathogens and antimicrobial resistance.
Solution
DevsHealth offers an AI-driven drug discovery platform, DevsHealth OS, that integrates advanced data analytics, molecular modeling, and continuous learning to accelerate the design of antiviral and antimicrobial candidates. The platform automates the generation of large antiviral libraries through its DAPP solution, enabling rapid iteration and optimization of drug candidates. By reducing the time, cost, and risk associated with traditional discovery pipelines, DevsHealth aims to expand the pipeline of treatments for global health challenges, including emerging viruses and resistant infections.
Target Audience
Primary customers are pharmaceutical companies, biotech firms, and research institutions focused on developing treatments for infectious diseases and antimicrobial resistance.
Features
- AI-powered data analysis that extracts insights from diverse biological and chemical datasets to identify promising molecular targets
- High‑precision molecular modeling and simulation tools for in silico design and optimization of drug candidates
- Continuous learning framework that updates models with new experimental data to improve prediction accuracy over time
- DAPP module for ultra‑fast creation of antiviral compound libraries tailored to emerging pathogens
- Integrated workflow that streamlines candidate selection, synthesis planning, and preclinical evaluation
- Scalable cloud infrastructure supporting parallel processing of large compound libraries